Interleukin‐33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species‐mediated inhibition of nuclear factor kappa‐B signal and stemness properties
Article in MedComm (May 2024)
The most recent citing publications are shown below. View all 31 publications that cite this research output on Dimensions.
Molecular and immunological mechanisms of clonal evolution in multiple myeloma
Article in Frontiers in Immunology (September 2023)
Past, Present, and a Glance into the Future of Multiple Myeloma Treatment
Article in Pharmaceuticals (March 2023)